Analyzing IBS to Identify Biomarkers and Microbiome Signatures

Overview

About this study

Microbiota from fecal samples from IBS-D patients, in combination with vitamin D supplementation added to our 3-D immunocompetent intestinal models will establish a high fidelity disease model to achieve our long-term goal to understand the relationship between gut microbiome, vitamin D levels, host gene expression and IBS-D symptoms that could ultimately be used as a testing platform for treatment and prevention.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

  • IBS-D subjects:
    • Patients who fulfill IBS-D criteria, without causes of active inflammation.
    • active symptoms for at least 2 months
    • diagnosed at least 6 months prior to enrollment
  • Healthy Control:
    • Healthy control patients should have no active infection or inflammation.

Exclusion criteria:

  • does not meet inclusion criteria
  • will not participate in blood draw, stool sample donation, or endoscopy
  • history of acute illness within 3 months of testing
  • any fecal transplant history

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Amy Foxx-Orenstein, D.O.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions